— Net sales of $2.6 billion, down 18.8% year-over-year — Reported earnings per share of $4.22 and adjusted earnings per share(1) of $1.35 — Strong year-to-date free cash flow generation — Full-year net sales and adjusted earnings per share outlook raised AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural […]

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study GlobeNewswire July 31, 2025 PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces the

(NASDAQ:DYAI), JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the

(NASDAQ:RGEN), WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign's machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in

(NASDAQ:IFRX), JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx

(NASDAQ:PBM), NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety

(Other OTC:MRMD),(OTC US:MRMD),(CNSX:MRMD.CN),(CNSX:MRMD),(CBOE:TILT.NE),(PinkSheets:TLLTF), NORWOOD, Mass., July 31, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed,” “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, today announced a strategic agreement with TILT Holdings (“TILT”) (CBOE: TILT) (OTCPK: TLLTF) that will expand the distribution of the Company's award-winning portfolio of medical marijuana

(TSX-V:FW), TORONTO, ON, July 31, 2025 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV: FW) (“Flow Capital” or the “Company”) is pleased to announce a C$15.0 million senior secured note in Common Wealth Pension Services Inc. (dba “Common Wealth”), a SaaS company serving the Canadian group retirement market, with a first tranche advance of C$4.0 million.

(CNSX:URM),(CNSX:URM.CN),(Boerse Frankfurt – Freiverkehr:IOR),(Pinksheets:FAUMF),(PinkSheets:FAUMF), Vancouver, British Columbia , July 31, 2025 (GLOBE NEWSWIRE) — First American Uranium Inc. (CSE: URM) (FSE: IOR) (OTCPK: FAUMF) (the “Company”) announces, further to its news release of July 21, 2025 and effective August 6, 2025, the Company will consolidate the common shares in the capital of the Company (the

(NASDAQ:AVXL), New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) 'time saved' by early-start ADAS-Cog13 difference: âˆ'5.43 (P = 0.0035), ADCS-ADL difference: +9.50 (P < 0.0001) Restoring impaired autophagy as early event, preceding amyloid-beta and tau Oral presentation at the Alzheimer's Association International Conference (AAIC) 2025 NEW YORK, July 31, 2025